Immunic, Inc. · NASDAQ:IMUX

Immunic — Corporate Update (April 2023)

29 slides from Immunic's corporate update, Apr 5, 2023

  1. Slide 1: Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis

    Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis NASDAQ: IMUX | April 5, 2023

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities

  3. Slide 3: CALDOSE-1: Final Week 50 Maintenance Phase Data

    Vidofludimus Calcium in Ulcerative Colitis (UC) CALDOSE-1: Final Week 50 Maintenance Phase Data

  4. Slide 4: CALDOSE-1: Phase 2 Trial Design in UC

    CALDOSE-1: Phase 2 Trial Design in UC NCT03341962 Induction Phase Maintenance Phase Placebo (n=60) Placebo Patients with Optional 10 mg IMU-838 QD open-label (n=60) symptomatic remission extension at weeks 10 mg IMU-838 QD period to 10 or 22 obtain long- 30 mg IMU-838 QD R (n=60) R term safety: (n=1

  5. Slide 5: Dose-Linear Increase in Clinical Remission at Week 50 For Vidofludimus Calcium as Compared to Placebo

    Dose-Linear Increase in Clinical Remission at Week 50 For Vidofludimus Calcium as Compared to Placebo Clinical Remission at Week 50 Clinical Remission at Week 50 Full Analysis SetMP (NPBO = 27, N10 = 45, N30 = 40) 100% Data Set: 10 mg 30 mg Placebo (n-evaluable/n-total of IMU-838 IMU-838 80% (N=18/2

  6. Slide 6: Exploratory Statistical Analysis of Clinical Remission

    Exploratory Statistical Analysis of Clinical Remission Statistically Significant Difference in Favor of 30 mg Vidofludimus Calcium Versus Placebo 30 mg of vidofludimus calcium found to be statistically superior to achieve clinical remission during maintenance Clinical Remission at Week 50 treatment

  7. Slide 7: 10-Week Induction Phase Data: UC Patients Without Concomitant Corticosteroids Responded Well

    10-Week Induction Phase Data: UC Patients Without Concomitant Corticosteroids Responded Well (Previously Reported in June 2022) 𝚫 11.4% The graphs use the concurrent use of corticosteroids, as used as stratification factor for randomization provided by the investigator, not actual use of concurrent

  8. Slide 8: Comparison to Other Maintenance Data

    Comparison to Other Maintenance Data Vidofludimus Calcium Shows Competitive Maintenance Data in UC 70% Clinical remission active 𝚫 33.7% 60% Clinical remission placebo 61.5% 50% 𝚫 19.8% 𝚫 25.9%* 𝚫 28.9%* 𝚫 30.0% 40% 𝚫 14.4% 43.8% 44.8% 𝚫 18.5% 41.8% 42.0% 𝚫 23.2% 38.4% 37.0% 30% 34.3% 27.8%…

  9. Slide 9: Steroid-Free Clinical Remission at Week 50

    Steroid-Free Clinical Remission at Week 50 Vidofludimus Calcium Superior as Compared to Placebo Steroid-Free Clinical Remission at Steroid-Free Clinical Remission Week 50 Full Analysis SetMP (NPBO = 27, N10 = 45, N30 = 40) 100% Data Set: 10 mg 30 mg Placebo (n-evaluable/n-total of IMU-838 IMU-838 (N

  10. Slide 10: Steroid-Free Clinical Remission at Week 50

    Steroid-Free Clinical Remission at Week 50 Subgroup Analysis of Patients Who Received Corticosteroids During Induction Phase Clinical Remission of Induction Steroid Clinical Remission Sub-Group at Week 50 Modified Full Analysis SetMP (NPBO = 17, N10 = 22, N30 = 22) 100% 10 mg 30 mg Placebo IMU-838 I

  11. Slide 11: Endoscopic Healing at Week 50

    Endoscopic Healing at Week 50 Vidofludimus Calcium Superior as Compared to Placebo Endoscopic Healing Endoscopic Healing at Week 50 Full Analysis SetMP (NPBO = 27, N10 = 45, N30 = 40) 100% Data Set (n- 10 mg 30 mg Placebo N=19/26 evaluated/n-total of IMU-838 IMU-838 (N=17/21) 80% 73.1% group) (N=28/

  12. Slide 12: Exploratory Statistical Analysis of Endoscopic Healing

    Exploratory Statistical Analysis of Endoscopic Healing Statistically Significant Difference in Favor of 30 mg Vidofludimus Calcium Versus Placebo 30 mg of vidofludimus calcium found to be statistically superior to achieve endoscopic healing at week 50 as Endoscopic Healing at Week 50 compared to pla

  13. Slide 13: Summary Efficacy Results Maintenance Phase CALDOSE-1 Trial

    Summary Efficacy Results Maintenance Phase CALDOSE-1 Trial § Maintenance phase results confirm the previous hypothesis (from the analysis of patients without concomitant corticosteroid use during the induction phase) that vidofludimus calcium provides a benefit regarding clinical remission, as compa

  14. Slide 14: Incidence of TEAEs Lower in Both 10 mg and 30 mg Vidofludimus Calcium Groups

    Incidence of TEAEs Lower in Both 10 mg and 30 mg Vidofludimus Calcium Groups Than in Placebo Group Number of patients with TEAEs, serious TEAEs, and TEAEs of special interest Safety SetMP (NPBO = 27, N10 = 45, N30 = 40) Placebo 10 mg IMU-838 30 mg IMU-838 Total TEAE N (n) TEAE (%) TEAE N (n) TEAE (%

  15. Slide 15: No Increase in Liver Events Observed as Compared to Placebo

    No Increase in Liver Events Observed as Compared to Placebo Placebo 10 mg IMU-838 30 mg IMU-838 Total TEAE N (n) TEAE (%) TEAE N (n) TEAE (%) TEAE N (n) TEAE (%) TEAE N (n) TEAE (%) Hepatobiliary Cholecystitis 0 0 1(1) 2.2% 0 0 1(1) 0.9% disorders Aspartate aminotransferase 1(1) 3.7% 0 0 0 0 1(1) 0.

  16. Slide 16: Absence of Hy's Law Cases

    Absence of Hy’s Law Cases Indicates Low Potential for Drug-Induced Hepatotoxicity Hy’s Law Plot: Alanine Aminotransferase (ALT) Hy’s Law Plot: Aspartate Aminotransferase (AST) Safety Analysis SetMP (NPBO = 27, N10 = 45, N30 = 40) Safety Analysis SetMP (NPBO = 27, N10 = 45, N30 = 40) Peak Bilirubin t

  17. Slide 17: No Increase in Renal Events Observed as Compared to Placebo

    No Increase in Renal Events Observed as Compared to Placebo Placebo 10 mg IMU-838 30 mg IMU-838 Total TEAE N(n) TEAE (%) TEAE N(n) TEAE (%) TEAE N(n) TEAE (%) TEAE N(n) TEAE (%) Blood creatinine increased 1(1) 3.7% 0 0 0 0 1(1) 0.9% Investigations Blood urine present 0 0 1(1) 2.2% 0 0 1(1) 0.9% Red

  18. Slide 18: Summary Safety Results Maintenance Phase CALDOSE-1 Trial

    Summary Safety Results Maintenance Phase CALDOSE-1 Trial § Administration of vidofludimus calcium during maintenance phase found to be safe and well-tolerated § Incidence of TEAEs for vidofludimus calcium comparable to placebo § Very few serious TEAEs observed § As compared to placebo, the incidence

  19. Slide 19: Pipeline Update and Outlook

    Immunic Therapeutics Pipeline Update and Outlook

  20. Slide 20: Pipeline Focus on Vidofludimus Calcium and IMU-856

    Pipeline Focus on Vidofludimus Calcium and IMU-856 § Immunic to focus on the rapidly advancing vidofludimus calcium and IMU-856 programs § Positive data from the CALDOSE-1 trial of vidofludimus calcium shown today support strategic focus on gastroenterology and neurology indications § Totality of av

  21. Slide 21: Summary: Several Clinical Data Readouts Expected in 2023

    Summary: Several Clinical Data Readouts Expected in 2023 Initial phase 1b celiac disease data IMU-856 expected in the current quarter Mode of action and molecular target to IMU-856 be presented in the context of an upcoming scientific GI congress Interim analysis of phase 2 CALLIPER IMU-838 trial in

  22. Slide 22: Q&A Session

    Q&A Session

  23. Slide 23: Thank You!

    Thank You! Immunic, Inc. Immunic AG 1200 Avenue of the Americas Lochhamer Schlag 21 New York City, NY 10036 82166 Gräfelfing (Munich) USA Germany Jessica Breu Head of IR & Communications Immunic Australia Pty. Ltd. Phone: +49-89-2080477-09 Melbourne Email: ir@imux.com Australia Web: www.imux.com 23

  24. Slide 24: CALDOSE-1: Further Information

    Vidofludimus Calcium in Ulcerative Colitis (UC) CALDOSE-1: Further Information

  25. Slide 25: CALDOSE-1: Clinical Phase 2 Trial in Ulcerative Colitis (UC)

    CALDOSE-1: Clinical Phase 2 Trial in Ulcerative Colitis (UC) NCT03341962 Coordinating investigator: Primary endpoint: Dr. Geert D’Haens Proportion of patients (AMC Amsterdam) with clinical remission Patient population: (symptomatic remission and § Male and female patients, endoscopic remission) Cond

  26. Slide 26: Reminder About Corticosteroids Use in the CALDOSE-1 Trial

    Reminder About Corticosteroids Use in the CALDOSE-1 Trial A During Induction Phase B During Maintenance Phase § Concomitant use of corticosteroids was § Re-randomization of vidofludimus calcium allowed: patients to 10 and 30 mg doses (independent of - At doses ≤20 mg prednisolone equivalent their in

  27. Slide 27: Patients Per Treatment Group

    Patients Per Treatment Group CALDOSE-1 Maintenance Phase When reaching Randomized patients symptomatic remission Randomized patients maintenance phase induction phase N=112 at week 10 or 22 N=263 10 mg IMU-838 30 mg IMU-838 Placebo assigned/completed assigned/completed assigned/completed N=45/35 N=4

  28. Slide 28: Patient Demographics and Prior Treatment History

    Patient Demographics and Prior Treatment History CALDOSE-1 Maintenance Phase 10 mg 30 mg Placebo Characteristics IMU-838 IMU-838 N=27 Patients dosed in maintenance phase N=45 N= 40 who received corticosteroids during induction phase Mean age (years) 40.1 (14.1) 39.7(13.1) 43.8 (14.1) 50 Male (N in %

  29. Slide 29: Multivariate Analysis Shows Concomitant Steroid Use is Main Factor for Outcome of Clinical Remission

    Multivariate Analysis Shows Concomitant Steroid Use is Main Factor for Outcome of Clinical Remission in Induction Phase Multivariate analysis shows that concomitant steroids Estimation of odd ratios for vidofludimus calcium have highest impact on clinical remission data achieving clinical remission

Immunic — Corporate Update (April 2023) on 6ix